1. Home
  2. SRRK vs ENIC Comparison

SRRK vs ENIC Comparison

Compare SRRK & ENIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRRK
  • ENIC
  • Stock Information
  • Founded
  • SRRK 2012
  • ENIC 2016
  • Country
  • SRRK United States
  • ENIC Chile
  • Employees
  • SRRK N/A
  • ENIC N/A
  • Industry
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • ENIC Electric Utilities: Central
  • Sector
  • SRRK Health Care
  • ENIC Utilities
  • Exchange
  • SRRK Nasdaq
  • ENIC Nasdaq
  • Market Cap
  • SRRK 4.2B
  • ENIC 3.7B
  • IPO Year
  • SRRK 2018
  • ENIC N/A
  • Fundamental
  • Price
  • SRRK $43.07
  • ENIC $2.84
  • Analyst Decision
  • SRRK Strong Buy
  • ENIC Hold
  • Analyst Count
  • SRRK 7
  • ENIC 1
  • Target Price
  • SRRK $40.43
  • ENIC $3.90
  • AVG Volume (30 Days)
  • SRRK 1.2M
  • ENIC 312.8K
  • Earning Date
  • SRRK 11-12-2024
  • ENIC 10-29-2024
  • Dividend Yield
  • SRRK N/A
  • ENIC 8.60%
  • EPS Growth
  • SRRK N/A
  • ENIC N/A
  • EPS
  • SRRK N/A
  • ENIC 0.01
  • Revenue
  • SRRK N/A
  • ENIC $5,287,759,941.00
  • Revenue This Year
  • SRRK N/A
  • ENIC $16.86
  • Revenue Next Year
  • SRRK N/A
  • ENIC N/A
  • P/E Ratio
  • SRRK N/A
  • ENIC $4.64
  • Revenue Growth
  • SRRK N/A
  • ENIC 8.81
  • 52 Week Low
  • SRRK $6.76
  • ENIC $2.51
  • 52 Week High
  • SRRK $46.19
  • ENIC $3.47
  • Technical
  • Relative Strength Index (RSI)
  • SRRK 69.26
  • ENIC 57.79
  • Support Level
  • SRRK $40.95
  • ENIC $2.80
  • Resistance Level
  • SRRK $44.22
  • ENIC $2.90
  • Average True Range (ATR)
  • SRRK 2.57
  • ENIC 0.05
  • MACD
  • SRRK -0.12
  • ENIC 0.01
  • Stochastic Oscillator
  • SRRK 73.14
  • ENIC 78.26

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

About ENIC Enel Chile S.A. (Each representing 50 shares of)

Enel Chile SA is an electricity utility company, which through its subsidiaries and affiliates is engaged in the generation, transmission and distribution of electricity businesses in Chile. It operates through two segments including Generation Business and Distribution and Network Business. The Generation Business Segment is comprised of a group of electricity companies that own electricity generating plants, whose energy is transmitted and distributed to end customers. The Distribution and Network Reportable Segment is comprised of a group of electricity companies operating under a public utility concession.

Share on Social Networks: